Sunday 18 October 2026
Export ACIU’s income statement to Excel — free account
AC Immune
ACIU Healthcare Biotechnology
AC Immune’s revenue for fiscal 2025 (year ended December 2025) was $4.3 million, down 86.1% from fiscal 2024. In the quarter to June 2026, revenue grew 29.7%, EPS grew 9.52% and free cash flow grew 4.66%, each against the same quarter a year earlier.
2.39
0.06
−2.45%
Follow ACIU
AC Immune (ACIU) P/E ratio
AC Immune has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 39.4× (September 2016) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 12.7× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 37.2× | 16.31% |
| FY2015 | 32.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| 24 more quarters | Free account |
Against its own ten years
Low 0.0×
High 39.4×
Ten-year median
0.0×
Current reading's percentile
85
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACIU AC Immune | n/m |
| LCTX Lineage Cell Therapeutics, Inc. compare | n/m |
| SABS SAB Biotherapeutics, Inc. compare | n/m |
| BBOT BridgeBio Oncology Therapeutics, Inc compare | n/m |
| VNDA Vanda Pharmaceuticals Inc. compare | n/m |
| XFOR X4 Pharmaceuticals, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| IKT Inhibikase Therapeutics, Inc. compare | n/m |
| RCKT Rocket Pharmaceuticals, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)